Tempus AI, Inc. (TEM) fair value analysis
Nasdaq · Updated 2026-10-19
TEM price how computed
Valuation status
No fair-value estimate yetTEM has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for TEM yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $64.72
- Sector
- Healthcare
- 12-month range
- $41.55–$91.58
- Market cap
- $11.4B
- From 52-week high
- -29.3%
- Shares outstanding
- 175M
- Rank in Healthcare by quality score
- #161 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Tempus AI, Inc. is a healthcare technology company that uses artificial intelligence and machine learning to analyze medical data and assist with clinical decision-making and treatment planning. The company operates primarily in the United States, serving healthcare providers, patients, and life sciences organizations through its AI-powered platform and data analytics services.
TEM currently ranks #161 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $11.4B
- P/E (trailing)
- n/m
- Revenue (TTM)
- $1.43B
- Net margin
- -17.8%
- EPS (TTM)
- $-0.63
- Gross margin
- 64.4%
- Debt / equity
- 3.25
- Revenue growth (3-yr avg)
- 60.4%
- Shares outstanding
- 175M
Derived indicators how computed
- Quality grade
- D
- Margin trend
- Expanding
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 35 · neutral
- 50-day average
- $67.82
- 200-day average
- $56.79
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-03
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+14.6%)
2026-03 ▲ beat (+35.0%)
2025-12 ▲ beat (+80.0%)
2025-09 ▲ beat (+38.9%)
2025-06 ▲ beat (+12.0%)
2025-03 ▲ beat (+11.1%)
2024-12 ▼ miss (-17.5%)
2024-09 ▲ beat (+10.7%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 10 buy · 9 hold · 1 sell (20 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $74.9
- Target vs last price
- +15.7%
What our data shows for TEM
- Shares are trading in the middle of their 12-month price range of $41.55–$91.58.
- The 14-day relative strength index sits at a neutral 35.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- TEM's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the TEM conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for TEM showed a shift in trend state this week, with the 50/200-day trend moving from uptrend to mixed. The valuation verdict remains awaiting full valuation as of this assessment period.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is TEM stock undervalued?
TickrTrends has no fair-value estimate for TEM yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is TEM's TickrTrends verdict?
TEM is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does TEM compare to other Healthcare stocks?
TEM ranks #161 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is TEM overbought or oversold?
TEM's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does TEM report earnings next?
TEM's next earnings report is scheduled for 2026-11-03, per the published earnings calendar.
Does TEM usually beat earnings estimates?
Over its last 8 reported quarters TEM beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about TEM?
Of 20 analysts covering TEM, 10 rate it a buy, 9 a hold and 1 a sell - buy-leaning, with a consensus price target of $74.9 (+15.7% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.